Several targets, such as TIGIT and BTLA, have a similar frequency of expression on CD8+ T cells in healthy donors, peripheral blood from patients with GBM, and tumor-infiltrating lymphocytes (TILs). This evidence concerns the gene BTLA and neoplasm.